

BIOLOGICAL ACTIVITIES OF HYDRAZONE DERIVATIVES IN THE NEW MILLENNIUM

Vandana Jugran Negi*, Ashok Kumar Sharma, Jeetendra Singh Negi, Veerma Ram

*Faculty of Pharmaceutical Sciences, Sardar Bhagwan Singh Post Graduate Institute of Biomedical Sciences and Research, Balawala, Dehradun, India

Corresponding author*: vandananeji111@gmail.com

This article is available online at www.ssjiournals.com

ABSTRACT:




Hydrazones are present in many of the bioactive heterocyclic compounds that are of wide interest because of their diverse biological and clinical applications. This created interest in researchers who have synthesized variety of hydrazone derivatives and screened them for their various biological activities viz. anticonvulsant, antidepressant, analgesic, anti-inflammatory, antiplatelet, antimalarial, antimicrobial, antimycobacterial, anticancer, vasodilator, antiviral, antischistosomiasis, anti-HIV, anthelmintic, antidiabetic and trypanocidal activities. Hydrazones possessing an azomethine – $\text{NHN}=\text{CH}$ - proton constitute an important class of compounds as target structures and evaluated their biological activities. These observations have been guiding for the development of new hydrazones that possess varied biological activities.

Keyword: Hydrazone, hydrazides-hydrazones, biological activity, isoniazid.

1. Introduction :


Hydrazones are of wide interest because of their diverse biological and clinical applications. This created interest in researchers who have synthesized variety of hydrazone derivatives and screened them for their various biological activities. In the present study, we have made an attempt to collect biological properties of hydrazone derivatives reported in the new millennium.

Hydrazide-hydrazone compounds are not only intermediates but they are also very effective organic compounds in their own right. When they are used as intermediates, coupling products can be synthesized by using the active hydrazone component of $-\text{CONHN}=\text{CH}-$ azomethine group¹. Many effective compounds, such as iproniazide (i) and isocarboxazide (ii), are synthesized by reduction of hydrazide-hydrazones. Iproniazid, like INH is used in the treatment of tuberculosis. It has also displays an antidepressant effect and patient appear to have a better mood during the treatment. Another clinically effective hydrazide-hydrazones is nifuroxazide (iii), which is used as an intestinal antiseptic.




Hydrazone have been demonstrated to possess, among other, anticonvulsant, antidepressant, analgesic, anti-inflammatory, antiplatelet, antimalarial, antimicrobial, antimycobacterial, anticancer, vasodilator, antiviral, antischistosomiasis, anti-HIV, anthelmintic, antidiabetic, and trypanocidal activities. For example, 2-Chloroquinolinyll hydrazone derivative are anticonvulsants² ribavirin hydrazone derivatives are anticancer³, hydrazones of indane-1,3-dione are anticoagulant and antimicrobial⁴, 4-arylhydrazono-2-pyrazoline-5-one derivatives are antitubercular activity⁵. In addition, some of the new hydrazide hydrazones which are recently synthesized were active against *M. tuberculosis* H37Rv between the concentrations of 0.78-6.25 $\mu\text{g/ml}$.⁶ Synthesis of a series of hydrazide- hydrazones via the

reaction of cyanoacetyl hydrazine with bromo (4-methoxyacetophenone) reported for antidepressant, sedative and analgesic activities⁷.



Isoniazid (iv)




hydrazide-hydrazones (v)

Isonicotinic acid hydrazide (isoniazid,INH) (iv) has very high in vivo inhibitory activity towards *M. tuberculosis* H37rv. Sah and Peoples synthesized INH(iv)hydrazide-hydrazones(v) by reacting INH with various aldehyde and ketones⁸. These compounds were reported to have inhibitory activity in mice infected with various strains of *M. tuberculosis*. They also showed less toxicity in these mice than INH. Buu-Hoi *et al.* synthesized some hydrazide-hydrazones that were reported to have lower toxicity than hydrazides because of the blockage of $-NH_2$ group. These findings further support the growing importance of the synthesis of hydrazide-hydrazones compound^{9,10}. Iron is necessary for the biochemical reactions of living organisms. Desferrioxamine is an agent which is used for the treatment of a complication called "Iron Overload Disease". Researchers have synthesized hydrazones of INH by using various aldehydes and their iron complexes and evaluated these complexes for their antitumoral activity¹⁰. It has been known that the hydrazide (like INH) form α -ketoglutaric acid and form hydrazones with vitamin B6 and pyruvic acid. It is clinically important that when tuberculosis patient are treated with INH, reaction of INH with vitamin B6 leads to formation of a hydrazone and development of vitamin B6 deficiency, therefore, patients who are treated with INH should be administered vitamin B6. This review critically evaluates the pharmacological activity of hydrazones that were reported in the past ten years.

2. Biological activity:

2.1. Anticonvulsant Activity: Epilepsy is a common neurological disorder and a collective term given to a group of syndromes that involve spontaneous, intermittent, abnormal electrical

activity in the brain. The pharmacotherapy of epilepsy has been archived during the last decade. Furthermore, although for the last twenty years new antiepileptic drugs have been introduced into clinical practice, the maximal electroshock (MES) test and the subcutaneous pentylenetetrazole (scPTZ) test are the most widely used animal models of epilepsy to characterize the anticonvulsant activity. Suresh kumar *et al* (2010) worked on 2-Chloroquinolinyl Hydrazone (vi) derivatives having anticonvulsant activity. These compounds were believed to interact at two locations on a putative binding site designated as hydrogen binding domain and hydrophobic binding area as proposed by Dimmock *et al.*³



2-Chloroquinolinyl Hydrazone (vi)

Nadeem Siddiqui *et al* (2008) synthesized a series of 2-(1H-indol-3-yl)acetyl-N-(substituted phenyl) hydrazine carbothioamides and their related heterocyclic derivatives. The anticonvulsant evaluation of compounds in mice at 30, 100 and 300 mg kg⁻¹ by i.p. MES (maximal electroshock seizure), drugs used as standards, phenytoin and carbamazepine. Compounds with the electron withdrawing chloro substituent at the ortho position to the amino group led to considerable increase in the activity but were relatively more toxic. The presence of a bulkier electron donating methoxy group at para position of the amino group resulted in an increase in activity. This may be due to the increase in lipophilicity of the compound. The effect of the methyl group was found to be different in the three groups of compounds. In the case of triazole derivatives, the activity was as follows: o ~ m > p, with no effect on toxicity. In the case of oxadiazole derivatives, only p-substituted compound was active, and in thiadiazole derivatives it followed the order o ~ p > m. It shows that hydrazone-indole based heterocyclic derivatives were found to have encouraging anticonvulsant activity¹¹.


Jegadeesan Vaigunda Ragavendran *et al* (2007) designed and synthesized anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore and evaluated by using intraperitoneal (i.p.) maximal electroshock-induced seizure (MES), subcutaneous pentylenetetrazole (scPTZ), subcutaneous strychnine (scSTY), and intraperitoneal

picrotoxin (ipPIC)-induced seizure threshold tests. All of the compounds were ineffective in the MES test. Most of the compounds were found to be effective in the scSTY and ipPIC models and very few compounds showed protection in the sc PTZ model. The study reported that the synthesis of pharmacophoric combinations of phthalimide-GABA-anilide/hydrazones as candidate anticonvulsants. Of the two series of pharmacophorichybrids, the phthalimideGABA-anilides were found to be more effective than the corresponding phthalimide-GABA-hydrazone derivatives¹².

DarpanKaushik *et al* (2010) synthesized and evaluated the anticonvulsant activity of N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides. They tried to develop aryl acid hydrazidehydrazones as new congeners to join this, as this group mimics the cyclic ureide group of semicarbazone. Among the compounds, the aryl derivative 5a exhibited activity against both the MES and scPTZ models. When the C-4 position i.e. paratothe aryl ring was substituted with electron withdrawing group the compounds were found to be more potent and active in both the models as compared to electron donating group, while compound with p-methoxy group was found to be weakly active in the MES model only and shows no activity in the scPTZ model. With increasing electronegativity, the compound was found to be more potent [13Ravi Kulandasamy *et al* (2009) evaluate the anticonvulsant activity of thirty nine new 3,4-di(substituted)oxy-N2,N5-bis(substituted)thiophene-2,5-dicarbohydrazide, by using intraperitoneal (ip) administration in three seizure models, which include maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) and 6 Hz screens.¹³

2.2 Antidepressant Activity: Iproniazide, isocarboxazide and nialamide, which are hydrazide derivatives, exert their action by inhibiting the enzyme monoamine oxidase (MAO). Inhibition results in increased levels of norepinephrine, dopamine, tyramine and serotonin in brain neurons and in various other tissues. There have been many reports on the antidepressant / MAO-inhibiting the activity of hydrazones derived from substituted hydrazides and reduction products. Ten new arylidenehydrazides which were synthesized by reacting 3-phenyl-5-sulfonamidoindole-2-carboxylic acid hydrazide with various aldehydes, evaluated for their antidepressant activity. 3-Phenyl-5-sulfonamidoindole-2-carboxylic acid 3,4-methylenedioxy / 4-methyl /

4-nitrobenzylidene-hydrazide showed antidepressant activity at 100 mg/kg¹⁴



R. M. Mohareb *et al* (2010) Synthesized of hydrazide-hydrazone derivatives and evaluated for antidepressant activity. The reaction of cyanoacetylhydrazine with ω-bromo(4-methoxyacetophenone) gave the hydrazidehydrazone derivative. This compound reacted with either potassium cyanide or potassium thiocyanide to give the cyanide or thiocyanide derivatives. The reaction of compound with either hydrazine hydrate or phenyl hydrazine gave the hydrazine derivatives. The latter compounds underwent a series of heterocyclization when react with different reagents to give 1,3,4-triazine and pyridine derivatives. Evaluations of synthesized compounds was done for antidepressant activity by using Porsolt's forced-swimming test After 60 min of i.p. administration, some compounds shown below showed mild non-significant antidepressant activity at high doses and were active, compared with the control group, using saline as negative control. The rest of compounds failed to display antidepressant properties in the swimming test⁷.

2.3 Antimalarial Activity: Keeping the above facts in mind, Gemma *et al.* (2006) synthesized a new series of N1-arylidene-N2-quinolyl- and N2-acrydinyldiazones and tested in vitro for their antimalarial properties against a series of Plasmodium falciparum strains, namely the chloroquine-sensitive D10 and 3D7, and the CQ-resistant W2 and K1. The results indicated that N-(7-Chloro-quinolin-4-yl)- N'-(4-pyrrolidin-1-ylmethyl-benzylidene)-hydrazine was the most active compound of the series¹⁵.

A series of N1-arylidene-N2-quinolyl and N2-acrydinyldiazones were synthesized and tested for their antimalarial properties. The new synthesized compounds showed an antiplasmodial activity against the chloroquine-sensitive D10 strain in the same range of chloroquine(CQ)¹⁶.

2.4. Antimicrobial Activity: The resistance of bacteria against antimicrobial agents has become a widespread medical problem especially as nosocomial pathogens. Treatment options for these infections are often limited, especially in


debilitated and immunocompromised patients. The search for new antimicrobial agents will consequently always remain as an important and challenging task for medicinal chemists.

Olayinka O. Ajani *et al* (2010) developed a simple and efficient method for the synthesis of various 2-quinoxalinone-3-hydrazone derivatives using microwave irradiation technique and evaluated for their antimicrobial activities against the organisms *B. cereus* (NCIB6349), *B. stearothermophilus* (NCIB 8222), *B. subtilis* (NCIB 3610), *B. anthracis* (LIO), *Bacillus polymyxa* (LIO), *Corynebacterium pyogenes* (LIO), *Streptococcus faecalis* (NCIB775), *S. aureus* (NCIB 8588), *Clostridium sporogenes* (LIO), *E. coli* (NCIB 86), *P. fluorescens* (NCIB3756), *K. pneumoniae* (NCIB 418), *S. dysenteriae* (LIO), *P. aeruginosa* (NCIB 950) and *C. albicans* (LIO) by using agar diffusion technique. The most active antibacterial agent was 3-[2-[1-(6-chloro-2-oxo-2H-chromen-3-yl)ethylidene]hydrazinyl]quinoxalin-2(1H)-one, 7 while 3-[2-(propan-2-ylidene)hydrazinyl]quinoxalin-2(1H)-one, 2 appeared to be the most active antifungal agent¹⁷.

Madalina Veronica Angelus *et al* (2010) prepared a new aryl-hydrazone, N-(2-pyridinecarbaldehyde)-N0-[4-(4-chlorophenyl)sulfonyl]benzoyl]-hydrazone (L) and its Cu(II), Co(II) and Ni(II) complexes and antibacterial activity was studied against gram-positive bacteria: *Staphylococcus aureus*, *Bacillus subtilis* and gram-negative bacteria: *Pseudomonas aeruginosa*, *Escherichia coli* by using minimum inhibitory concentrations (MICs) method. The obtained results show that the ligand (L) has a weak action on all the tested microorganisms. The activity of N-(2-pyridinecarbaldehyde)-N0-[4-(4-chlorophenyl)sulfonyl]benzoyl]-hydrazone (L) becomes more pronounced when coordinated to the metal ions.¹⁸

Ummuhan Ozdemir Ozmen *et al* (2008) synthesized new sulfonylhydrazone derivatives and their nickel complexes and evaluated their antibacterial activity against gram-positive bacteria (*Staphylococcus aureus*, *Bacillus subtilis*, *Bacillus magaterium*) and gram-negative bacteria (*Salmonella enteritidis*, *Escherichia coli*) by using minimum inhibitory concentration (MICs) method. The antibacterial result showed that the sulfonyl hydrazone compounds possess a broad spectrum of activity against the tested bacteria at MIC values between 145 and 683 µg/ml. The presence of electron densities on donor atoms (as

O, S, N, etc.) in ligands contributes positively to the increase of the activity of compound against bacteria. But the decrease of the electron densities by the coordination through the donor atoms causes the lower activities of complexes than ligand's¹⁹.



hydrazones and its chelates

Aakash Deep *et al* (2010) designed biphenyl-4-carboxylic acid hydrazide-hydrazone and evaluated for their in vitro antimicrobial activity against two gram negative strain (*Escherichia coli* and *Pseudomonas aeruginosa*) and two Gram positive strain (*Bacillus subtilis* and *Staphylococcus aureus*) and fungus strain (*Candida albicans* and *Aspergillus niger*). The structural requirements for antibacterial and antifungal activity are different for substituted hydrazides. Most antibacterial compounds showed the least antifungal activity and compounds being the most active antifungal compounds have shown the least antibacterial activity. The presence of electron withdrawing groups (-NO₂, -Cl, Br) on aromatic ring improved the antimicrobial activity of compounds²⁰.

Metwally *et al.* (2006) synthesized a new series of 2-arylquinoline-4-carboxylic acid hydrazide-hydrazones and evaluated for their in vitro antimicrobial activity against *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans*. Out of the synthesized compounds 6-chloro-2-(4-methoxyphenyl)quinoline-4-carboxylic acid (4-nitrobenzylidene)-hydrazide was found to be most potent²¹.

Masunari *et al.* (2007), fourteen p-substituted benzoic acid [(5-nitro-thiophen-2-yl)-methylene]-hydrazides were synthesized and tested in vitro for antimicrobial activity against standard (ATCC 25923) and multi drug-resistant (3SP/R33) strains of *Staphylococcus aureus* by Masunari *et al.* The results of antimicrobial study indicated that 4-Acetyl-benzoic acid [(5-nitro-thiophen-2-yl)-methylene]-hydrazide was the most active compound²².

Zareef *et al.* (2008) synthesized derivatives of acylhydrazine such as substituted-2-mercapto-1,3,4-oxadiazoles, their corresponding ester, amide and benzenediasulfonamides and tested

them for antimicrobial activity which showed that one of the acylhydrazinebenzene diasulfonamide derivative was having appreciable antimicrobial activity²³

2.5. Antimycobacterial Activity: Tuberculosis is a serious health problem that causes the death of some three million people every year worldwide. In addition to this, the increase in *M. tuberculosis* strains resistant to front-line antimycobacterial drugs such as rifampin and INH has further complicated the problem, which clearly indicates the need for more effective drugs for the efficient management of tuberculosis.

Sriram *et al.* (2006), various diclofenac acid hydrazones and amides were synthesized and evaluated for in vitro and in vivo antimycobacterial activities against *Mycobacterium tuberculosis*. The results showed that 1-cyclopropyl-6-fluoro-8-methoxy-7-[[N4-(2-(2-(2,6-dichloro phenylamino)phenyl)acetyl)-3-methyl]-N1-piperazinyl]-4-oxo-1,4-dihydro-3-quinoline carboxylic acid was found to be the most active compound in vitro than first line antitubercular drug isoniazid. In the in vivo animal model, decreased the bacterial load in lung and spleen tissues²⁴.

Nayyar *et al.* (2007) synthesized two new series of 2- substituted quinolines 4-(adamantan-1-yl) group and evaluated in vitro for their antimycobacterial activities against drug-sensitive *M. tuberculosis* H37Rv strain. Compound 4-adamantan-1-yl-quinoline-2-carboxylic acid (2-chloro benzylidene) hydrazide inhibited drug-sensitive *Mycobacterium tuberculosis* H37Rv at 1.00 µg/mL (99 % inhibition) and was equipotent to standard drug isoniazid²⁵.

Manvar *et al.* (2008) During the coumarin-4-acetic acid benzylidenehydrazides as anti-tubercular agents against *Mycobacterium tuberculosis* H37Rv strain using the BACTEC 460 system, (7-Hydroxy-2-oxo- 2H-chromen-4-yl)-acetic acid (3-nitro-benzylidene)-hydrazide (**30**) was found to be most potent with MIC and percentage inhibition of 6.25 µg/mL and 93 %²⁶.

AhmetOzdemir *et al* (2010) synthesized some novel hydrazone derivatives by the reaction of (5,6,7,8-tetrahydronaphthalen-1-yl) acetic acid hydrazide with various benzaldehydes which gave 5,6,7,8-tetrahydronaphthalen acetic acid benzylidenehydrazide derivatives and evaluated their antituberculosis activity which showed that compounds having -OH and -NO₂ in ortho and meta position of aromatic ring having high antituberculosis activity and low cytotoxicity²⁷.

SrivastavaRitu *et al* (2010) synthesized twelve aryl acetic acid hydrazones and tested first time for their activity against mycobacterium. The compounds showed moderate activity against H37 RV strain of *Mycobacterium tuberculosis* at a concentration of 10 µM²⁸.

2.6 Antiviral Activity: HIV infection and AIDS represent one of the first diseases for which the discovery of drugs was performed entirely via a rational drug design approach. Current treatment regimens are based on the use of two or more drugs that belong to group of inhibitors termed as highly active antiretroviral therapy (HAART). Some thiourea compounds were reported to be non-nucleoside inhibitors (NNIs) of the reverse transcriptase (RT) enzyme of the human immunodeficiency virus (HIV). Such hydrazones have been reported to be the potent inhibitors of ribonucleotidoreductase activity. N-Arylaminoacetylhydrazones and O-acetylated derivatives of sugar N-arylaminoacetylhydrazones were synthesized and evaluated for their antiviral activity against Herpes simplex virus-1 (HSV-1) and hepatitis-A virus (HAV). Some compounds revealed the highest antiviral activity against HAV-27 and HSV-1.²⁹

Al-Macrosaur *et al.* (2007), HIV-1 integrase (IN) is a critical enzyme for viral replication. This initiated Masawi *et al.* to screen salicylhydrazide class of compounds for their potent HIV-1 integrase inhibitory activity. The results of screening showed (4-Phenyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid (2-hydroxy-benzylidene)-hydrazide, displayed weak HIV-1 integrase inhibitory activity³⁰.

2.7 Antischistosomiasis: Schistosomiasis causes debilitating nutritional, hematologic and cognitive deficits, with substantial morbidity and mortality in populations. There are five species of flatworms that cause schistosomiasis. *Schistosoma mansoni*, *S. intercalatum*, *S. haematobium*, *S. japonicum* and *S. mekongi*. *Schistosoma mansoni* and *S. intercalatum*, *S. japonicum* and *S. mekongi* cause intestinal and Asian intestinal schistosomiasis, respectively. *S. haematobium* resides in the venous plexus, which causes urinary schistosomiasis³¹.

9-Acridanone hydrazones have been developed by Hoffmann-La Roche (Basel-Switzerland). One of these compounds (RO 15-5458/000) was administered at two dose levels 25 mg and 15 mg/kg body-weight to *S. mansoni* infected vervet-monkeys³².

In addition, same compounds were found to be effective against *S. mansoni* in mice, killing

almost all the skin schistosomules, when administered at the dose of 100mg/kg. In experiments carried out with Cebus monkeys, the compound RO 15-5458 / 000 was shown to be fully effective at 25 mg/kg.³³

2.8 Antianthrax Activity: Inhalation of *Bacillus anthracis* spores is often fatal if not appropriately treated in a timely fashion. Inhaled spores in the lung alveoli are phagocytosed by alveolar macrophages and transported to the lymph nodes, where the spores germinate and multiply. The bacteria release a toxin that kills host macrophages, disabling the host immune system and thereby allowing the bacteria to escape the lymph node defense barrier to reach the blood system causing bacteraemia and toxemia, which rapidly kills the host. Anthrax toxin consists of three proteins: protective antigen (PA), edema factor (EF) and lethal factor (LF). The inhibition of LF proteolytic activity is a promising method for treating exposure to *Bacillus anthracis* spores. In light of above facts, Hanna *et al.* (2007) generated series of hydrazones and analyzed them for their potential anthrax lethal factor inhibition. The study showed that showed an appreciable activity.³⁴

2.9 Trypanocidal Activity: African trypanosomes are the causative agent of sleeping sickness in human and Nagana in cattle. Chemotherapy of African trypanosomiasis still relies heavily on drugs developed decades ago and some of them are toxic. In addition, the emergence of drug resistant trypanosome stains in animals has been widely reported. Therefore, the development of new antitrypanosomal drugs is urgently required. Keeping this in mind, Caffery *et al.* (2002) screened a non-peptidyl acyl hydrazide proteinase inhibitory library of 500 compounds for inhibition of brucipain (major cysteine proteinase). The compounds with IC₅₀ values <40 μ M were tested for their efficacy against blood stream forms of *Trypanosoma brucei* in cell culture. Some of the synthesized acyl hydrazides showed 50% or more inhibition of trypanosome replication at <1 μ M. The trypanocidal activity of most effective compound 4-Nitro-benzoic acid [4-(4-nitrophenyl)-cyclopenta-1,3-dienylmethylene]-hydrazide was comparable to those of commercial drugs sumarin and diminazine aceturate.³⁵

This stimulated Leite *et al.* (2006) to synthesize a novel series of thiosemicarbazone and aminoacyl-thiazolidones derivatives. Biological evaluation of synthesized compounds indicated that 2-[N'-[2-(4-Chloro-phenyl)sulfanyl]-ethylidene]-hydrazino}-5-methyl-thiazol-4-one exhibited

significant in vitro activity against epimastigote *Trypanosoma cruzi*.³⁶

2.10 Leishmanicidal Activity: According to the World Health Organization (TDR, 2005), leishmaniasis, caused by species of the genus *Leishmania* (Sarcomastigophora, Kinetoplastida) an emerging and uncontrolled Category I diseases, constitutes a major public health problem, causing significant morbidity and mortality in Africa, Asia and the Americas. The present treatments available for leishmaniasis are far from ideal.

In the search for new rational chemotherapeutic alternatives, Visbal *et al.* (2008) synthesized two novel trans [Pt(Hpy1)2(Cl)2] and trans [Pt(Hpy2)2 (Cl)2] complexes by the reaction of K₂PtCl₄ with sterol hydrazone ligands 20-hydrazone-pyridin-2-yl-5 α -pregnan-3 β -ol (Hpy1) and 22-hydrazone-pyridin-2-yl-cholesterol-5-ene-3 β -ol (Hpy2). These organic compounds are specific inhibitors of sterol methyl transferase (SMT). Promastigotes of *Leishmania (L.) mexicana* were treated for 48 h with 10 μ M of the sterol hydrazones Hpy1 or Hpy2 alone or coordinated to Pt. Hpy1 produced higher leishmanicidal activity than Hpy2 (39% growth inhibition vs. 16%), which significantly increased (71%, $p < 0.001$) when the complex trans- [Pt(Hpy1)2(Cl)2] was used.³⁷

2.11 Analgesic, Antiinflammatory and Antiplatelet Activity: In the 1980's, hydrazone type containing compounds such as BW 755c and CBS 1108 were described as dual COX/5-LO inhibitors which present analgesic and anti-inflammatory activities. In fact, some evidences that the hydrazone moiety present in derivative possess a pharmacophoric character for the inhibition of COX.

Ali Almasirad *et al* (2005) a series of N-Arylhydrazone derivatives of mefenamic acid (a known non steroidal anti-inflammatory) synthesized by replacement of carboxylic acid moiety of mefenamic acid with an N-arylhydrazone group and evaluated their analgesic and anti-inflammatory activity by using abdominal constriction test (writhing test) and carrageenan-induced rat paw edema test. The pharmacological results showed that pyridine ring at the aryl moiety of the arylhydrazone having good analgesic activity in comparison to mefenamic acid. Compounds possessing the 4-tolyl or 4-fluorophenyl moiety are more active than 4-bromophenyl and 4-N, N -dimethylaminophenyl. The anti-inflammatory evaluation of seven most potent compounds showed that replacement of carboxylic acid group of

mefenamic acid with N-arylhydrazone moiety cannot produce any advantage in the anti-inflammatory property of this drug³⁸].

K.K Sivakumar *et al* (2010) worked on analgesic activity of some (4Z)-3-methyl-1-[(2-oxo-2H-chromene-4-yl)carbonyl]-1H-pyrazole-4,5-dione 4-[(4-substitutedphenyl) hydrazone] some of them showed significant analgesic activity compared with the standard drug (indomethacin 5mg/kg) at the dose level of 50 mg/kg on oral administration. Pharmacological evaluation was done by using Acetic acid-induced writhing model in mice which showed that the presence of 4-chloro, 4-bromo, 3,4-dichloro, 3,4-dibromo and 4-methyl group in the aromatic ring of 4-position of the pyrazole-hydrazone nucleus gave rise to an increased analgesic activities³⁹.

Suroor A. Khan *et al* (2009) synthesized hydrazone derivatives of quinoxalinone and evaluated for anti-inflammatory activity by using carageenan induced rat paw edema method which showed that compounds having methoxy group at the para position showed comparatively good percentage of inhibition of edema than the other synthesized compounds⁴⁰. Treatment of 3-cyano acetylindole with diazonium salts of 3-phenyl-5-amino pyrazole and 2-amino pyrazole gave the corresponding hydrazones. Out of the synthesized compounds, 3-(1H-Indol-3-yl)-3-oxo-2-[(5-phenyl-2H-pyrazol-3-yl)-hydrazone]-propionitrile was found to possess appreciable analgesic and anti-inflammatory activity.⁴¹

The antiplatelet activity of novel tricyclic acylhydrazone derivatives was evaluated by their ability to inhibit platelet aggregation of rabbit platelet-rich plasma induced by platelet-activating factor (PAF) at 50 nM. Benzylidene-/4'-bromobenzylidene-3-hydroxy-8-methyl-6-phenylpyrazolo [3,4-b]thieno-[2,3-d]pyridine-2-carbohydrazide were evaluated at 10 μ M, presenting, respectively, 10.4 and 13.6% of inhibition of the PAF-induced platelet aggregation⁴². The evaluation of platelet antiaggregating profile led to identification of a new potent prototype of antiplatelet derivative, that is benzylidene 10H-phenothiazine-1-carbohydrazide (IC₅₀=2.3 μ M), which acts in the arachidonic acid pathway probably by inhibition of platelet COX-1 enzyme. Additionally, the change in para-substituent group of acylhydrazone framework permitted to identify a hydrophilic carboxylate derivative and a hydrophobic bromo derivative as two new analgesics that are more potent than dipyrene, which is the standard, possessing selective peripheral or central mechanism of action⁴³.

2.12. Antitumoral Activity: Cancer remains a major public health issue at the beginning of the 21st century. Chemotherapy is one of the ways to fight against cancer. Therefore, the need for accelerated development of new, more effective as well as less toxic chemotherapeutic agents has appeared.

Liang-Wen Zheng *et al* (2009) synthesized a series of substituted pyrazole-5-carbohydrazide hydrazone derivatives and discovered a potent apoptosis inducer in A549 lung cancer cells. The results showed that (E)-1-(4-tert-butylbenzyl)-N-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide possessed the highest growth inhibitory effect and induced apoptosis of A549 cells⁴⁴.

Vicini *et al.* (2006) synthesized several benzo[d]isothiazolehydrazones and evaluated for their potential antiretroviral activity. Among the synthesized compounds benzo[d]isothiazole-3-carboxylic acid (4-methoxy-benzylidene)-hydrazide was found to be the most potent antiproliferative compound and the fragment –CO–NH–N=CH–2-hydroxyphenyl was identified as being very important for biological activity, suggesting intramolecular hydrogen bond formation or favorable mutual disposition between two important centers in the pharmacophore⁴⁵.

2.13. Vasodilator Activity: Conventional therapy to treat hypertension often involves arterial vasodilation. It is important to find new vasodilators with a potential for clinical use. A new bioactive compound of the N-acylhydrazone class, 3, 4-methylenedioxybenzoyl-2-thienylhydrazone, named LASSBio-294, and was shown to have inotropic and vasodilatory effects. New derivatives of LASSBio-294 were designed and tested on the contractile responses of rat vascular smooth muscle in vitro. Phenylephrine-induced contractions of aorta was inhibited by the derivatives N-methyl-2-thienylidene-3,4-methylenedioxy-benzoyl hydrazine, named LASSBio-785 and N-allyl-2-thienylidene-3,4-methylenedioxy-benzoyl hydrazine, named LASSBio-788. The concentrations necessary to cause 50% reduction in maximum contractions (IC₅₀) were 10.2 \pm 0.5 and 67.9 \pm 6.5 μ M. Vasodilation induced by both derivatives is likely to be mediated by a direct effect on smooth muscle because it was not dependent on the integrity of vascular endothelium. LASSBio-785 was seven times more potent than the reference compound LASSBio-294 (IC₅₀ = 74 μ M) in producing an endothelium-independent vasodilator effect⁴⁶.

2.14 Antidiabetic Activity: Glycogen synthase kinase-3 (GSK-3), a protein in the serine/threonine kinase family, is broadly expressed and serves many functions within the human body. Among some of the diseases that GSK-3 may affect are Alzheimer's disease, diabetes, various cancer types and neurological disorders. One function of GSK-3 is to mediate the conversion of glycogen to glucose and is regulated in part by insulin signaling. In patients with insulin resistance, GSK-3 is constitutively active, which leads to an increase in plasma glucose levels and hyperglycemia. Inhibitors of GSK-3 could reduce glucose levels by mimicking the effect of insulin signaling on GSK-3 and thus could be used as anti-diabetic treatments. In view of above, Smalley *et al.* (2006) synthesized a set of novel heterocyclic pyrimidylhydrazones as inhibitors of glycogen synthase kinase-3 (GSK-3) with the most active compound exhibiting low nanomolar activity. Quantum mechanical calculations indicate that of the conformational factors that could determine binding affinity, the planarity of the phenyl ring in relation to the central core and the conformation of the hydrazone chain are the most influential⁴⁷.

References

1. Singh, V., Srivastava, V.K., Palit, G., Shanker, K., Coumarin congeners as antidepressants. *Arzneim-Forsch. Drug. Res.* 1992; 42: 993-6.
2. Kumar S., Bawai S., Drabu S., Kumar R. and Machwal L. 2 Chloroquinolinyldiazine derivative as anticonvulsant. *Acta Poloniae Pharmaceutica Drug Res.* 2010; 67:567-3.
3. Wei-Yong Liu a, Hai-Ying Li B, Bao-Xiang Zhao a, Dong-Soo Shin c, Song Lian a, and Jun-Ying Miaonovel. Ribavirin hydrazone derivatives and anti-proliferative activity against A549 lung cancer cells, *Carbohydrate Res.* 2009; 344:1270-5.
4. Jubie S., Meena S., Ramaseshu K.V., Jawahar N. and Vijaykumar S., Hydrazone indane-1,3-dione having anticoagulant and antimicrobial activity. *Indian Journal of Chemistry.* 2010; 49B:1261-3.
5. Kucukguzela Sq. Güniz, Rollasa S, Erdenizb H, Kirazb M, Ekincic A. Cevdet, Vidinc A. Some 4-arylhydrazono-2-pyrazoline-5-one derivatives obtained from heterocyclic amines, tested against *Mycobacterium avium*. *Eur. J. Med. Chem.* 2007; 35: 761-1.
6. Kaymakçioğlu K.B., Oruç, E.E., Unsalan, S., Kandemirli, F., Shvets, N., Rollas, S., Anatholy, D. Synthesis and characterization of novel hydrazone-hydrazones and the study of their structure-antituberculosis activity. *Eur. J. Med. Chem.* 2006; 41: 1253-1261.
7. Mohareb R. M., El-Sharkawy K. A., Hussein M. M. and El-Sehrawi H. M. Hydrazone derivatives as antidepressant, sedative and analgesic agents. *J. Pharm. Sci. & Res.* 2010; 2 :185-196.
8. Sah, P.P.T.; Peoples, S.A. Isonicotinyldiazones as antitubercular agents and derivatives for identification of aldehydes and ketones. *J. Am. Pharm. Assoc.* 1954; 43: 513-24.
9. Bavin E.M.; Drain, D.J.; Seiler, M.; Seymour, D.E. Some further studies on tuberculostatic compounds. *J. Pharm. Pharmacol.* 1954; 4: 844-55.
10. Buu-Hoi, P.H.; Xuong, D.; Nam, H.; Binon, F.; Royer, R. Tuberculostatic hydrazides and their derivatives. *J. Chem. Soc.* 1953; 1358-64.
11. Siddiqui Nadeem, Alam M., Shamsheer, Ahsan W., 2-(1*H*-indol-3-yl)acetyl-*N*-(substituted phenyl) hydrazine as anticonvulsant. *Acta Pharm.* 2008; 58:445-54.
12. Ragavendran J.V., Sriram D., Patel S.K., Reddy I. V., Bharathwajan N., Stables J., Yogeewari P., Design and synthesis of anticonvulsants from a combined phthalimide- GABA- anilide and hydrazine Pharmacophore. *European Journal of Medicinal Chemistry* 2007; 42: 146-51.
13. Kaushik Darpan, Khan Suroor Ahmad, Chawla Gita, Kumar Suresh. N'-[(5-chloro-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: Synthesis and anticonvulsant activity. *Eur. J. Med. Chem.* 2010; 45: 3943-49.
14. Ergenç, N.; Günay, N.S. Synthesis and antidepressant evaluation of new 3-phenyl-5 sulfonamidoindole derivatives, *Eur. J. Med. Chem.* 1998; 33: 143-8.
15. Gemma, S., Kukreja, G., Fattorusso, C., Persico, M., Romano, M.P., Altarelli, M., Savini, L., Campiani, G., Fattorusso, E., Basilico, N., Taramelli, D., Yardley, V. and Butini, S.. Synthesis of N1- amylidene-N2-quinolyl- and N2- acryldinyldiazones as potent antimalarial agents active against CQ-resistant *P. falciparum* strains. *Bioorg. Med. Chem. Lett.* 2006; 16: 5384-8.
16. Walcourt, A.; Loyevsky, M.; Lovejoy, D.B.; Gordeuk, V.R.; Richardson, D.R. Novel aroyldiazine and thiosemicarbazone iron chelators with anti-malarial activity against

- chloroquine-resistant and -sensitive parasites. *Int. J. Biochem. Cell Biol.* 2004; 36: 401-7.
17. Olayinka O. Ajani, Craig A. Obafemi b, Obinna C. Nwinyi c, David A. Akinpelu. Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives. *Bioorganic & Medicinal Chemistry* 2010; 18: 214-21.
 18. Madalina Veronica Angelusiua, Stefania-Felicia Barbuceanub, Constantin Draghici, Gabriela Laura Almajan. New Cu(II), Co(II), Ni(II) complexes with aroyl- hydrazone based ligand. Synthesis, spectroscopic characterization and in vitro antibacterial evaluation. *Eur. J. Med. Chem* 2010; 45:2055-62.
 19. OzmenUmmuhanOzdemir and OlgunGulcin. Sufonylhydrazone derivatives and their nickel complexes as a antibacterial agents. *SpectrochimicaActa.* 2008; 70: 641-5.
 20. Deep A., Jain S., Sharma P.C., Verma P., Kumar M and Dora C.P. Design and biological evaluation of biphenyl-4-carboxylic acid hydrazide-hydrazone for antimicrobial activity. *Acta Poloniae Pharmaceutica-Drug Res.* 2010; 67(3): 255-9.
 21. Metwally, K.A., Abdel-Aziz, L.M., Lashine, E.M., Husseiny, M.I. and Badawy R.H..Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents. *Bioorg. Med. Chem.* 2006;14: 8675-82.
 22. Masunari, A. and Tavares, L.C. A new class of nifuroxazideanalogues : synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant *Staphylococcus aureus*. *Bioorg. Med. Chem.* 2007; 15: 4229-36.
 23. Zareef, M., Iqbal, R., Mirza, B., Khan, K.M., Manan, A., Asim, F. and Khan, W. Synthesis and antimicrobial activity of some derivatives of acylhydrazine including novel benzenediazasulfonamides. 2008; 141-52.
 24. Sriram, D., Yogeeswari, P. and Devakaram, R.V. Synthesis, *in vitro* and *in vivo* antimycobacterial activities of diclofenac acid hydrazones and amides. *Bioorg. Med. Chem.* 2006; 14: 3113-18
 25. Nayyar, A., Monga, V., Malde, A., Coutinho, E. and Jain, R. Synthesis, anti-tuberculosis activity and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines. *Bioorg. Med. Chem.* 2007; 15: 626-40.
 26. Manvar, A., Malde, A., Verma, J., Virsodia, V., Mishra, A., Upadhyay, K., Acharya, H., Countinhe, E. and Shah, A. Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4- acetic acid benzylidene hydrazides. *Eur. J. Med. Chem* 2008; 3: 342-4.
 27. Ozemir A., Kalancikli Z.A., Zitouni G.T., RevialG. Synthesis of some novel hydrazone derivatives and evalution of their antituberculosis activity. *Marmara Pharmaceutical Journal.* 2010; 14: 79-83.
 28. Srivastava R., Pandeya S.N., Singh A.K., Anantham Sam. Synthesis of some new acid hydrazone and their activity against mycobacterium. *International Journal of Chemistry Research.* 2010; 2(1):18-19.
 29. Liang-Wen Zheng , Ling-Ling Wub, Bao-Xiang Zhao, Wen-Liang Dong, Jun Ying Miao. Synthesis of novel substituted pyrazole- 5- carbohydrazide hydrazone derivatives and discovery of a potent apoptosis inducer in A549 lung cancer cells. *Bioorg. Med. Chem.* 2009; 17: 1957-1962.
 30. Al-Macrosaur, L.Q., Dayam, R., Taheri, L., Witvrouw, M., Debyser, Z. and Neamati, N. Discovery of novel non-cytotoxic salicylhydrazine containing HIV-1 integrase Inhibitors. *Bioorg. Med. Chem. Lett.* 2007; 17: 6472-75.
 31. Friedman, J.F.; Mital, P.; Kanzaria, H.K.; Olds, G.R.; Kurtis, J.D. Schistosomiasis and pregnancy. *Trends Parasitol.* 2007;23: 159-64.
 32. Sulaiman, S.M.; Ali, H.M.; Homeida, M.M.; Bennett, J.L. Efficacy of a new Hoffmann-La Roche compound (RO-15-5458) against *Schistosomamansoni* (Gezira strain, Sudan) in vervet monkeys (*Cercopithecusaethiops*). *Trop. Med. Parasitol.* 1989; 40: 335-36.
 33. Pereira, L.H.; Coelho, P.M.; Costa, J.O.; de Mello, R.T. Activity of 9-acridanone-hydrazone drugs detected at the prepostural phase, in the experimental schistosomiasismansoni. *Mem. Inst.Oswaldo Cruz.* 1995; 90:425-28.
 34. Hanna, M.L., Tarasow, T.M. and Perkins, J.. Mechanistic differences between *in vitro* assays for hydrazone based small molecule Inhibitors of antrax lethal factor. *Bioorg. Med. Chem.* 2007; 35: 50-58.
 35. Caffrey, C.R., Schanz, M., Nkemgu-Njinkeng, J., Brush, M., Hausell, E., Cohen, F.E., Flaherty, T.M., Mckerrow, J.H. and Steverding, D. . Screening of acyl hydrazide proteinase inhibitors for antiparasitic activity

- against *Trypanosomabrucei*. *Int. J. Antimicrob. Agents*. 2002; 19: 227-251.
36. Leite, A.C.L., deLima, R.S., Moreira, D.R., Cardoso, M.V., de Brito, A.C.G., dos Santos, L.M.F., Hernandez, M.Z., Kipustok, A.C., de Lima, R.S. and Soares, M.B.P.. Synthesis, docking, and *in vitro* activity of thiosemiconbazone, aminoacyl-thiosemicarbazides and acyl-thiazolidones against *Trypanosomacruzi*. *Bioorg. Med. Chem.* 2006; 14:3749-57.
37. Visbal, G., Marchan, E., Maldonado, A., Simoni, Z. and Navarro, M. Synthesis and characterization of platinum-sterol hydrazone complexes with biological activity against *Leishmania (L.) mexicana*. *J. Inorg. Biochem.* 2008; 102:547-54.
38. Almasirad Ali, Tjik Mohammad, Bakhtiari Davood and Shafiee Abbas. Synthesis and analgesic activity of N-aryl hydrazone derivatives of mefenmic acid. *J Pharm Pharmaceut Sci.* 2005; 8(3):419-25.
39. Sivakumar K.K., Rajasekaran A., Ponnilarvarasan I., Somasundaram A., Sivasakthi R. and Kamalaveni S. Antimicrobial and analgesic activity of some (4Z)-3-methyl-1-[(2-oxo-2H-chromen-4-yl)carbonyl]-1H-pyrazole-4,5-dione 4-[(4-substitutedphenyl) hydrazone]. *Scholars research library*. 2010; 2(1):211-19.
40. Khan Suroor A., Mullick Pooja, PanditShabir and KaushikDarpan. Hydrazone derivatives of quinoxalinone as antimicrobial and anti-inflammatory agents. *Acta Poloniae Pharmaceutica-Drug Res.* 2009; 66(2):169-72.
41. Radhwan, M.A.A., Ragab, E.A., Sabry, N.M. and El-Shenawy, S.M. Synthesis and biological evaluation of new 3-substituted indole derivatives as potential anti-inflammatory and analgesic agents. *Bioorg. Med. Chem.* 2007; 15: 3832-41.
42. Todeschini, A.R.; Miranda, A.L.; Silva C.M.; Parrini, S.C.; Barreiro, E.J. Synthesis and evaluation of analgesic, anti inflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives. *Eur. J. Med. Chem.* 1998; 33 : 189-99.
43. Fraga, A.G.M.; Rodrigues, C.R.; Miranda, A.L.P.; Barreiro, E.J.; Fraga, C.A.M. Synthesis andpharmacological evaluation of novel heterocyclic acylhydrazone derivatives, designed as PAFantagonists. *Eur. J. Pharm. Sci.* 2000; 11: 285-290.
44. Liang-Wen Zheng , Ling-Ling Wub, Bao-Xiang Zhao, Wen-Liang Dong, Jun Ying Miao. Synthesis of novel substituted pyrazole-5-carbohydrazide hydrazone derivatives and discovery of a potent apoptosis inducer in A549 lung cancer cells. *Bioorg. Med. Chem* 2009; 17:1957-62
45. Vicini, P., Incerti, M., Doytchinova, I.A., Colla, P.L., Busonera, B. and Loddo, R.. Synthesis and antiproliferative activity of benzo[d] isothiazole hydrazones. *Eur. J. Med. Chem.* 2006; 41: 624-32
46. Silva A.G., Zapata-Suto, G.; Kummerle, A.E.; Fraga, C.A.M.; Barreiro, E.J.; Sudo, R.T. Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASS Bio-alogues. *Bioorg. Med. Chem.* 2005; 13: 3431-37.
47. Smalley, T.L., Jr., Peat, A.J., Boucheron, J.A., Dickerson, S., Garrido, D., Preugschat, F., Schweiker, S.L., Thomson, S.A. and Wang, T.Y. Synthesis and evaluation of novel heterocyclic Inhibitors of GSK-3. *Bioorg. Med. Chem. Lett.* 2006; 16:2091-94..